Body mass index and survival in a prospective randomized trial of localized high-risk renal cell carcinoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 25, Issue 9, 2016, Pages 1326-1332

  Donin, Nicholas M ^a   Pantuck, Allan ^a   Klopfer, Pia ^b   Bevan, Paul ^b   Fall, Barbara ^b   Said, Jonathan ^a   Belldegrun, Arie S ^a   Chamie, Karim ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Wilex Biotechnology GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; BODY MASS; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OBESITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; KAPLAN MEIER METHOD; KIDNEY TUMOR; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RENAL CELL CARCINOMA; RISK FACTOR; STATISTICAL MODEL;

ADIPOSITY; AGED; BODY MASS INDEX; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; OBESITY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84986212536     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-16-0226     Document Type: Review

References (45)

1. McLaughlin JK, Lipworth L, Tarone RE. Epidemiologic aspects of renal cell carcinoma. Semin Oncol 2006;33:527-33.
2. Booth A, Magnuson A, Fouts J, Foster M. Adipose tissue, obesity and adipokines: role in cancer promotion. Horm Mol Biol Clin Investig 2015;21:57-74.
3. Moyad MA. Obesity, interrelated mechanisms, and exposures and kidney cancer. Semin Urol Oncol 2001;19:270-9.
4. Li JJ, Gonzalez A, Banerjee S, Banerjee SK, Li SA. Estrogen carcinogenesis in the hamster kidney: role of cytotoxicity and cell proliferation. Environ Health Perspect 1993;101:259-64.
5. BergstromA, Hsieh CC, Lindblad P, Lu CM, Cook NR, Wolk A. Obesity and renal cell cancer-a quantitative review. Br J Cancer 2001;85:984-90.
6. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of bodymass index amongUS adults, 1999-2010.JAMA 2012;307:491-7.
7. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. The national health and nutrition examination surveys, 1960 to 1991. JAMA 1994; 272:205-11.
8. Gandaglia G, Ravi P, Abdollah F, Abd-El-Barr AE, Becker A, Popa I, et al. Contemporary incidence and mortality rates of kidney cancer in the United States. Can Urol Assoc J 2014;247-52.
9. Yoshiike N, Miyoshi M. [Epidemiological aspects of overweight and obesity in Japan-international comparisons]. Nihon Rinsho 2013;71: 207-16.
10. Washio M, Mori M, Mikami K, Miki T, Watanabe Y, Nakao M, et al. Risk factors for renal cell carcinoma in a Japanese population. Asian Pac J Cancer Prev 2014;15:9065-70.
11. Jung KW, Park S, Kong HJ, Won YJ, Boo YK, Shin HR, et al. Cancer statistics in Korea: incidence, mortality and survival in 2006-2007. J Korean Med Sci 2010;25:1113-21.
12. Kanazawa M, Yoshiike N, Osaka T, Numba Y, Zimmet P, Inoue S. Criteria and classification of obesity in Japan and Asia-Oceania. World Rev Nutr Diet 2005;94:1-12.
13. Marumo K, Kanayama H, Miyao N, Nakazawa H, Ozono S, Horie S, et al. Prevalence of renal cell carcinoma: a nation-wide survey in Japan, 2002. Int J Urol 2007;14:479-82.
14. Khang YH, Yun SC. Trends in general and abdominal obesity among Korean adults: findings from 1998, 2001, 2005, and 2007 Korea national health and nutrition examination surveys. J Korean Med Sci 2010;25: 1582-8.
15. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 2006;98:1331-4.
16. Jeon HG, Jeong IG, Lee JH, Lee CJ, Kwak C, Kim HH, et al. Prognostic value of body mass index in Korean patients with renal cell carcinoma. J Urol 2010;183:448-54.
17. Parker AS, Lohse CM, Cheville JC, Thiel DD, Leibovich BC, Blute ML. Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma. Urology 2006;68:741-6.
18. Kamat AM, Shock RP, Naya Y, Rosser CJ, Slaton JW, Pisters LL. Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors. Urology 2004;63:46-50.
19. Choi Y, Park B, Jeong BC, Seo SI, Jeon SS, Choi HY, et al. Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis. Int J Cancer 2013;132:625-34.
20. Hakimi AA, Furberg H, Zabor EC, Jacobsen A, Schultz N, Ciriello G, et al. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. J Natl Cancer Inst 2013;105:1862-70.
21. Donat SM, Salzhauer EW, Mitra N, Yanke BV, Snyder ME, Russo P. Impact of body mass index on survival of patients with surgically treated renal cell carcinoma. J Urol 2006;175:46-52.
22. Nagurney JT, Brown DF, Sane S, Weiner JB, Wang AC, Chang Y. The accuracy and completeness of data collected by prospective and retrospective methods. Acad Emerg Med 2005;12:884-95.
23. Brannon AR, Reddy A, Seiler M, Arreola A, Moore DT, Pruthi RS, et al. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer 2010;1:152-63.
24. Scelo G, Riazalhosseini Y, Greger L, Letourneau L, Gonzalez-Porta M, Wozniak MB, et al. Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nat Commun 2014;5:5135.
25. Horiguchi A, Asano T, Ito K, Sumitomo M, Hayakawa M. Fatty acid synthase over expression is an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma. J Urol 2008; 180:1137-40.
26. Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer 2015;15:484-98.
27. Lee WK, Byun SS, Kim HH, Rha KH, Hwang TK, Sung GT, et al. Characteristics and prognosis of chromophobe non-metastatic renal cell carcinoma: a multicenter study. Int J Urol 2010;17:898-904.
28. Pettus JA, Jang TL, Thompson RH, Yossepowitch O, Kagiwada M, Russo P. Effect of baseline glomerular filtration rate on survival in patients undergoing partial or radical nephrectomy for renal cortical tumors. Mayo Clin Proc 2008;83:1101-6.
29. Schips L, Lipsky K, Zigeuner R, Gidaro S, Salfellner M, Rehak P, et al. Does overweight impact on the prognosis of patients with renal cell carcinoma? A single center experience of 683 patients. J Surg Oncol 2004;88:57-61.
30. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 2012; 18:363-74.
31. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803-13.
32. McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, et al. The high-dose aldesleukin select trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res 2015;21:561-8.
33. Parekh N, Chandran U, Bandera EV. Obesity in cancer survival. Annu Rev Nutr 2012;32:311-42.
34. Psutka SP, Boorjian SA, Moynagh MR, Schmit GD, Costello BA, Thompson RH, et al. Decreased skeletal muscle mass is associated with an increased risk of mortality after radical nephrectomy for localized renal cell cancer. J Urol 2016;195:270-6.
35. Antoun S, Lanoy E, Iacovelli R, Albiges-Sauvin L, Loriot Y, Merad-Taoufik M, et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer 2013;119:3377-84.
36. Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebocontrolled study. J Clin Oncol 2010;28:1054-60.
37. Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010;21:1594-8.
38. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013;31:1539-47.
39. Antoun S, Lanoy E, Albiges-Sauvin L, Escudier B. Clinical implications of body composition assessment by computed tomography in metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2014;14:279-88.
40. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010; 102:605-13.
41. Pierorazio PM, Johnson MH, Ball MW, GorinMA, Trock BJ, Chang P, et al. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DiSSRM registry. Eur Urol 2015;68:408-15.
42. Crispen PL, Viterbo R, Fox EB, Greenberg RE, Chen DY, Uzzo RG. Delayed intervention of sporadic renal masses undergoing active surveillance. Cancer 2008;112:1051-7.
43. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the national cancer data base. Cancer 2008; 113:78-83.
44. Mendoza D, Newman RC, Albala D, Cohen MS, Tewari A, Lingeman J, et al. Laparoscopic complications in markedly obese urologic patients (amultiinstitutional review). Urology 1996;48:562-7.
45. Fazeli-Matin S, Gill IS, Hsu TH, Sung GT, Novick AC. Laparoscopic renal and adrenal surgery in obese patients: comparison to open surgery. J Urol 1999;162:665-9.